TCF7L2 and Hypoglycemia: Together the above results, it appears that DMC elicited its anti-hyperglycemic effects by enhancing GSK-3β activity and upregulating β-catenin expression, which in turn transactivated TCF7L2 that subsequently stimulated the secretion of GLP-1 and GIP leading to hypoglycemia.